Heidi Wang

Heidi Wang

Company: OBI Pharma

Job title: Chief Executive Officer

Seminars:

Pushing the Envelope: Developing Bi-Specific ADCs Using a Novel GlycOBIâ„¢ Platform 3:30 pm

Advantages of Dual Targeting: Enhancing efficacy by targeting multiple tumour proteins simultaneously, combats resistance with varied mechanisms of action, and broadens the target patient populations Challenges and Target Selection: Selecting the optimal targets and ideal formats remains complex, requiring precise identification of tumor-specific proteins for effective dual targeting Benefits of GlycOBIâ„¢ Platform: Producing homogenous ADCs…Read more

day: Conference Day 1

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.